Tomegavax, Inc.

Part of VIR Biotechnology, Inc.

UEI
NUE6Q16X2GL1
CAGE
6EXF1
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
Corporate family
SAM.gov registration date

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Tomegavax, Inc.'s 5 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
A cytomegalovirus-based therapeutic vaccine for chronic hepatitis b Grant · R44AI129232 National Institute of Allergy and Infectious Diseases $1,982,523
A cytomegalovirus vectored chagas disease therapeutic vaccine Grant · R43AI126963 National Institute of Allergy and Infectious Diseases $224,959
An effector memory t cell-based therapeutic cervical cancer vaccine Grant · R43CA180177 National Institutes of Health $224,671
A cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses Grant · R44CA180177 National Cancer Institute $1,876,513
CMV vectored herpes simplex vaccine Grant · R41AI109927 National Institutes of Health $299,863

Quick answers

What is Tomegavax, Inc.'s UEI?

Tomegavax, Inc.'s Unique Entity ID (UEI) in SAM.gov is NUE6Q16X2GL1.

What is Tomegavax, Inc.'s CAGE code?

Tomegavax, Inc.'s CAGE code is 6EXF1.

What is Tomegavax, Inc.'s primary NAICS code?

Tomegavax, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Is Tomegavax, Inc. registered in SAM.gov?

Tomegavax, Inc.'s SAM.gov registration expired on January 31, 2022.

Who is Tomegavax, Inc.'s parent company?

Tomegavax, Inc. is part of VIR Biotechnology, Inc.

What is Tomegavax, Inc.'s most recent federal award?

Tomegavax, Inc.'s most recent federal grant award is A cytomegalovirus-based therapeutic vaccine for chronic hepatitis b (R44AI129232), from National Institute of Allergy and Infectious Diseases, on March 3, 2017.

On GovTribe

See Tomegavax, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login